Zealand Pharma and Pepscan awarded EU grant of EUR 0.9 million for the joint development of peptide drugs
Zealand Pharma and Pepscan Holding NV announced the joint award of an EU research and development grant of EUR 860,000. The grant is awarded under the EUREKA Eurostars programme for the joint development of dual acting peptide drugs. The application by Zealand Pharma and Pepscan ranked no. 5 out of approximately 350 applications. With the collaboration, the two companies combine their competences to develop drugs to better treat chronic inflammations and gastrointestinal diseases, including Inflammatory Bowel Disease.
The grant awarded to Zealand Pharma and Pepscan covers a two-year development period, which is expected to lead to the identification of a lead dual acting peptide drug candidate ready for preclinical development.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.